Bruker Corporation (NASDAQ:BRKR) Shares Sold by Lbp Am Sa

LBP AM SA lessened its holdings in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 22.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,354 shares of the medical research company's stock after selling 8,416 shares during the quarter. LBP AM SA's holdings in Bruker were worth $1,183,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Linden Thomas Advisory Services LLC boosted its holdings in Bruker by 3.5% during the first quarter. Linden Thomas Advisory Services LLC now owns 19,356 shares of the medical research company's stock worth $808,000 after purchasing an additional 660 shares during the last quarter. Brown Advisory Inc. boosted its holdings in shares of Bruker by 18.9% in the first quarter. Brown Advisory Inc. now owns 2,410,137 shares of the medical research company's stock worth $100,599,000 after acquiring an additional 383,425 shares during the period. Envestnet Asset Management Inc. boosted its stake in Bruker by 7.3% during the first quarter. Envestnet Asset Management Inc. now owns 380,096 shares of the medical research company's stock valued at $15,865,000 after buying an additional 25,990 shares during the period. VELA Investment Management LLC lifted its holdings in shares of Bruker by 239.2% during the 1st quarter. VELA Investment Management LLC now owns 68,663 shares of the medical research company's stock worth $2,866,000 after acquiring an additional 48,422 shares during the last quarter. Finally, OneDigital Investment Advisors LLC lifted its stake in Bruker by 38.0% in the first quarter. OneDigital Investment Advisors LLC now owns 5,522 shares of the medical research company's stock worth $230,000 after purchasing an additional 1,520 shares during the last quarter. 79.52% of the stock is owned by institutional investors.

Bruker Stock Performance

NASDAQ:BRKR traded up $0.21 during mid-day trading on Friday, hitting $43.79. The company's stock had a trading volume of 3,517,253 shares, compared to its average volume of 1,758,729. The business's fifty day moving average is $39.16 and its two-hundred day moving average is $45.65. The stock has a market cap of $6.64 billion, a price-to-earnings ratio of 84.21, a PEG ratio of 2.92 and a beta of 1.18. Bruker Corporation has a 1 year low of $34.10 and a 1 year high of $72.94. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.57 and a quick ratio of 0.74.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The medical research company reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.01. Bruker had a return on equity of 19.47% and a net margin of 2.31%. The business had revenue of $801.40 million during the quarter, compared to analysts' expectations of $763.83 million. During the same quarter in the previous year, the firm posted $0.53 EPS. The company's revenue for the quarter was up 11.0% on a year-over-year basis. Analysts anticipate that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Monday, June 16th were given a $0.05 dividend. The ex-dividend date was Monday, June 16th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.46%. Bruker's dividend payout ratio (DPR) is currently 38.46%.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Stifel Nicolaus decreased their price objective on shares of Bruker from $57.00 to $48.00 and set a "hold" rating for the company in a report on Thursday, May 8th. Citigroup cut Bruker from a "strong-buy" rating to a "hold" rating and cut their target price for the stock from $50.00 to $40.00 in a research note on Thursday, May 22nd. Barclays dropped their target price on Bruker from $50.00 to $46.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. UBS Group lowered their target price on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Finally, Bank of America lowered their target price on Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. Six analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Bruker currently has an average rating of "Hold" and an average target price of $52.89.

Insider Activity

In other news, CEO Frank H. Laukien bought 2,608 shares of the stock in a transaction dated Friday, June 6th. The shares were acquired at an average cost of $38.36 per share, with a total value of $100,042.88. Following the purchase, the chief executive officer directly owned 38,462,171 shares in the company, valued at $1,475,408,879.56. The trade was a 0.01% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 27.30% of the stock is currently owned by insiders.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.